RU2003114752A - TREATMENT OF GASTROINTESTINAL STOMAL TUMORS - Google Patents

TREATMENT OF GASTROINTESTINAL STOMAL TUMORS

Info

Publication number
RU2003114752A
RU2003114752A RU2003114752/15A RU2003114752A RU2003114752A RU 2003114752 A RU2003114752 A RU 2003114752A RU 2003114752/15 A RU2003114752/15 A RU 2003114752/15A RU 2003114752 A RU2003114752 A RU 2003114752A RU 2003114752 A RU2003114752 A RU 2003114752A
Authority
RU
Russia
Prior art keywords
methylpiperazin
ylamino
benzamide
ylmethyl
pyridin
Prior art date
Application number
RU2003114752/15A
Other languages
Russian (ru)
Other versions
RU2301066C2 (en
Inventor
Элизабет БУХДУНГЕР
Рено КАПДЕВИЛЛЬ
Джордж Даниел ДЕМЕТРИ
Саса ДИМИТРЬЕВИС
Брайан Дж ДРУКЕР
Джонатан А. ФЛЕТЧЕР
Хейкки ЙОЕНСУУ
Сандра Лита СИЛБЕРМАН
Дейвид ТУВЕСОН
Майкл С. ХЕЙНРИЧ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2003114752A publication Critical patent/RU2003114752A/en
Application granted granted Critical
Publication of RU2301066C2 publication Critical patent/RU2301066C2/en

Links

Claims (8)

1. Применение 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I1. The use of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl] benzamide of the formula I
Figure 00000001
Figure 00000001
 или его фармацевтически приемлемой соли для приготовления фармацевтических композиций, предназначенных для лечения желудочно-кишечных стромальных опухолей.or a pharmaceutically acceptable salt thereof for the preparation of pharmaceutical compositions for the treatment of gastrointestinal stromal tumors. 2. Применение 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I2. Use of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl] benzamide of the formula I
Figure 00000002
Figure 00000002
 или его фармацевтически приемлемой соли для лечения желудочно-кишечных стромальных опухолей.or a pharmaceutically acceptable salt thereof for the treatment of gastrointestinal stromal tumors. 3. Способ лечения человека, страдающего желудочно-кишечными стромальными опухолями, отличающийся тем, что человеку, нуждающемуся в таком лечении, вводят эффективную в отношении желудочно-кишечных стромальных опухолей дозу 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I3. A method of treating a person suffering from gastrointestinal stromal tumors, characterized in that a person in need of such treatment is administered an effective dose of 4- (4-methylpiperazin-1-ylmethyl) -N- against gastrointestinal stromal tumors [4 -methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl] benzamide of the formula I
Figure 00000003
Figure 00000003
 или его фармацевтически приемлемой соли.or a pharmaceutically acceptable salt thereof. 4. Применение или способ по п.3, согласно которому вводят фармацевтически приемлемую кислотно-аддитивную соль 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I.4. The use or method according to claim 3, wherein the pharmaceutically acceptable acid addition salt of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidine is administered -2-ylamino) phenyl] benzamide of the formula I. 5. Применение или способ по п.3, согласно которому вводят метансульфонат 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I.5. The use or method according to claim 3, wherein 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino methanesulfonate is administered phenyl] benzamide of the formula I. 6. Применение или способ по п.3, согласно которому взрослому человеку вводят суточную дозу от 200 до 600 мг монометилсульфоната 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I.6. The use or method according to claim 3, according to which an adult is administered a daily dose of 200 to 600 mg of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3) monomethyl sulfonate -yl) pyrimidin-2-ylamino) phenyl] benzamide of the formula I. 7. Способ введения больному человеку, имеющему желудочно-кишечные стромальные опухоли 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I7. Method of administration to a sick person having gastrointestinal stromal tumors 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl ] benzamide of the formula I
Figure 00000004
Figure 00000004
 или его фармацевтически приемлемой соли, отличающийся тем, что больному человеку вводят ежедневно в течение периода времени, превышающего 3 месяца, фармацевтически эффективное количество 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I или его фармацевтически приемлемой соли.or its pharmaceutically acceptable salt, characterized in that the sick person is administered daily for a period of time exceeding 3 months, a pharmaceutically effective amount of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4- pyridin-3-yl) pyrimidin-2-ylamino) phenyl] benzamide of the formula I or a pharmaceutically acceptable salt thereof. 8. Способ по п.7, согласно которому вводят суточную дозу от 200 до 600 мг монометансульфоната 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида формулы I.8. The method according to claim 7, according to which a daily dose of 200 to 600 mg of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidine monomethanesulfonate is administered -2-ylamino) phenyl] benzamide of the formula I.
RU2003114752/15A 2000-10-27 2001-10-26 Method for treating gastrointestinal stromal tumor cases RU2301066C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
US60/243,810 2000-10-27

Publications (2)

Publication Number Publication Date
RU2003114752A true RU2003114752A (en) 2004-09-10
RU2301066C2 RU2301066C2 (en) 2007-06-20

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003114752/15A RU2301066C2 (en) 2000-10-27 2001-10-26 Method for treating gastrointestinal stromal tumor cases

Country Status (26)

Country Link
US (1) US6958335B2 (en)
EP (1) EP1332137B1 (en)
JP (1) JP4386635B2 (en)
KR (1) KR100885129B1 (en)
CN (1) CN1276754C (en)
AT (1) ATE321556T1 (en)
AU (2) AU2002218262B2 (en)
BR (1) BRPI0114870B8 (en)
CA (1) CA2424470C (en)
CY (1) CY1105055T1 (en)
CZ (1) CZ303944B6 (en)
DE (1) DE60118430T2 (en)
DK (1) DK1332137T3 (en)
ES (1) ES2260317T3 (en)
HK (1) HK1058193A1 (en)
HU (1) HU229106B1 (en)
IL (2) IL155029A0 (en)
MX (1) MXPA03003703A (en)
NO (1) NO324948B1 (en)
NZ (1) NZ525254A (en)
PL (1) PL209733B1 (en)
PT (1) PT1332137E (en)
RU (1) RU2301066C2 (en)
SK (1) SK287335B6 (en)
WO (1) WO2002034727A2 (en)
ZA (1) ZA200302155B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4477303B2 (en) * 2001-05-16 2010-06-09 ノバルティス アーゲー N- {5- [4- (4-Methyl-piperazino-methyl) -benzoylamide] -2-methylphenyl} -4- (3-pyridyl) -2-pyrimidin-amine and a combination comprising a chemotherapeutic agent Agent
PT1401416E (en) * 2001-06-29 2007-02-28 Ab Science Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd)
WO2003002108A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
EP1401413B1 (en) * 2001-06-29 2006-11-22 AB Science Use of tyrosine kinase inhibitions for treating allergic diseases
CA2452366A1 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
CA2452368A1 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
US20040242612A1 (en) * 2001-09-20 2004-12-02 Alain Moussy Use of tyrosine kinase inhibitors for promoting hair growth
US20040242601A1 (en) * 2001-09-20 2004-12-02 Alain Moussy Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
ES2269994T3 (en) * 2002-02-27 2007-04-01 Ab Science USE OF INHIBITORS OF THE TYROSINE KINASE, FOR THE TREATMENT OF CNS DISORDERS.
FR2844452A1 (en) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Modulating dendritic cell activity, e.g. for treatment of viral infections, NK-sensitive tumors or autoimmune diseases, using inhibitors or specific tyrosine kinases, e.g. c-abl, bcr/abl and c-kit
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
AU2004273605B2 (en) * 2003-09-19 2008-07-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
US20100210596A1 (en) * 2006-02-01 2010-08-19 Bluestone Jeffrey A Use of aminopyrimidine compounds in the treatment of immune disorders
US20080221132A1 (en) * 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
AU2007296743B2 (en) * 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (en) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 Composition containing quinazoline derivatives, preparation method and use
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
BR112013022552B1 (en) 2011-03-04 2021-11-23 Newgen Therapeutics, Inc QUINAZOLINE COMPOUNDS REPLACED WITH ALCINE, THEIR USE, PHARMACEUTICAL COMPOSITION, AND KIT
CN102918029B (en) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof
AU2013223749A1 (en) 2012-02-21 2014-09-11 Sun Pharmaceutical Industries Limited Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20140235631A1 (en) 2012-07-27 2014-08-21 Antonius Martinus Gustave Bunt Efflux inhibitor compositions and methods of treatment using the same
CA3172586A1 (en) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
US11285152B2 (en) 2017-07-20 2022-03-29 Kashiv Biosciences, Llc Stable oral pharmaceutical composition of imatinib
CA3089566A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of gastrointestinal stromal tumors
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CN114615982A (en) 2019-08-12 2022-06-10 德西费拉制药有限责任公司 Ripoctinib for treating gastrointestinal stromal tumor
CN115243681A (en) 2019-12-30 2022-10-25 德西费拉制药有限责任公司 Compositions of 1- (4-bromo-5- (1-ethyl-7- (methylamino) -2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl) -2-fluorophenyl) -3-phenylurea
LT4084778T (en) 2019-12-30 2024-01-25 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
KR102535840B1 (en) 2020-07-31 2023-05-23 (주)파로스아이바이오 Use of 2,3,5-Substituted Thiophene Compound for Prevention, Improvement or Treatment of Gastrointestinal Stromal Tumor
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (en) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (en) * 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
EP1117397A1 (en) * 1998-08-31 2001-07-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

Similar Documents

Publication Publication Date Title
RU2003114752A (en) TREATMENT OF GASTROINTESTINAL STOMAL TUMORS
JP2004512328A5 (en)
BRPI0114870B8 (en) use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-amino)phenyl]-benzamide for the manufacture of pharmaceutical compositions for treatment of gastrointestinal stromal tumors
KR102293847B1 (en) Use of masitinib for the treatment of a subpopulation of patients with amyotrophic lateral sclerosis
JP2008509187A5 (en)
RU2007108861A (en) TRIFTOMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS
RU2002123350A (en) Dipeptidnitrile Cathepsin K Inhibitors
JP2004525179A5 (en)
JP2005502643A5 (en)
JO2371B1 (en) 4-phenyl -pyridine derivatives
DK1227806T3 (en) Pharmaceutical preparation containing tolterodine and its use
CN1523991A (en) Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
ATE375341T1 (en) THIADIAZOLYLPIPERAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OR PREVENTION OF PAIN
JP2009532438A5 (en)
MD523G2 (en) New triazol pyrimidine derivatives, angiotension II antagonist, processes for preparation thereof, pharmaceutical compositions containg thereof
RU2002100058A (en) 1-Methylcarbapenem Crystal Derivatives
RU2008143703A (en) The use of c-Src inhibitors in combination with pyrimidylamine benzamide for the treatment of leukemia
ATE366107T1 (en) USE OF SULFODEHYDROABIETIC ACID TO TREAT INFLAMMATORY BOWEL DISEASE
RU2005138124A (en) DERIVATIVES OF TETRAHYDROCARBASOL AND THEIR PHARMACEUTICAL USE
HRP20100265T1 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
KR20060130619A (en) Combination of organic compounds
CA2504665A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
JP2006505582A5 (en)
RU2004126447A (en) TREATMENT OF RHEUMATOID ARTHRITIS
RU2008103549A (en) APPLICATION OF ACTIVATORS OF SOLUBLE GUANILATE CYCLASE FOR TREATMENT OF BLOOD SUPPLY DISORDERS